Dr. Raben is a board-certified professor of radiation oncology at the University of Colorado. He was recently named a U.S. News Top Doctor and was previously voted a Top Doctor in 5280 magazine.
Dr. Raben has developed nationally recognized clinical expertise over the past 20 years in the management of head and neck cancer (HNC), lung cancer and prostate/bladder cancers. He was the first to introduce intensity modulated radiation techniques for HNC and the first to spare the critical salivary glands and thyroid glands for patients undergoing radiation. For prostate cancer, he first introduced accelerated hypofractionated radiation to the prostate while simultaneously treating the lymph nodes, shortening overall treatment time with no increase in long-term side effects and with excellent outcomes. Dr. Raben also has extensive experience with low (LDR) and high dose rate (HDR) brachytherapy for prostate cancer.
His research focus has been on laboratory discoveries and innovative clinical trials offered only at UCHealth in areas such as high-risk, heavy smoker HNC patients, and offers approaches that will inhibit cancer DNA repair. He recently completed the first Phase I clinical trial in the U.S. with an oral DNA repair inhibitor (PARP inhibitor) and radiation for heavy smokers when combined with intensity modulated radiation (IMRT). He was a major contributor of the clinical design and implementation of a trial combing a biologic drug against growth factors with radiation that led to FDA approval of the drug called Erbitux.
Dr. Raben is honored to serve on the NRG Oncology head and neck steering committee and on the planning committee for the ASTRO HNC Symposiums, for which he served as chair in 2014 and 2016.. He is a member of the American Head and Neck Society and served on the steering committee for the 2017 6th International Congress of Head and Neck Oncology held in Barcelona, Spain. He is also a steering committee member of the GU section of the Southwest Oncology Group. He actively serves as an ASCO Ambassador for Multidisciplinary Cancer Management Courses (MCMC) to help educate underserved areas around the world in cancer care. He serves as the developmental therapeutics co-chair at the NRG. He is an ad hoc reviewer for the Journal of Clinical Oncology, JAMA Oncology, Oral Oncology, Head and Neck, International Journal of Radiation Oncology Biology Physics, Clinical Cancer Research and Cancer Research. He has authored over 140 publications with several additional manuscripts in review.
He received a B.A. in psychology from Duke University and his M.D. at Wake Forest University Bowman Grey School of Medicine. He completed an internship at the University of Hawaii and residency in radiation oncology at the Johns Hopkins Hospital, where he served as chief resident.